Authors:
Xiaobei ZhengRadiochemistry Lab, School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000 China

Search for other papers by Xiaobei Zheng in
Current site
Google Scholar
PubMed
Close
,
Feng DongDepartment of Nuclear Medicine, Gansu Academy of Medical Sciences, Lanzhou, 730050 China

Search for other papers by Feng Dong in
Current site
Google Scholar
PubMed
Close
,
Jing YangRadiochemistry Lab, School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000 China

Search for other papers by Jing Yang in
Current site
Google Scholar
PubMed
Close
,
Xiaojiang DuanRadiochemistry Lab, School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000 China

Search for other papers by Xiaojiang Duan in
Current site
Google Scholar
PubMed
Close
,
Tingting NiuRadiochemistry Lab, School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000 China

Search for other papers by Tingting Niu in
Current site
Google Scholar
PubMed
Close
,
Wangsuo WuRadiochemistry Lab, School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000 China

Search for other papers by Wangsuo Wu in
Current site
Google Scholar
PubMed
Close
, and
Jianjun WangRadiochemistry Lab, School of Nuclear Science and Technology, Lanzhou University, Lanzhou, 730000 China

Search for other papers by Jianjun Wang in
Current site
Google Scholar
PubMed
Close
Restricted access

Abstract  

This work reports the synthesis and preliminary biodistribution results of [131I]SIB-PEG4-CHC in tumor-bearing mice. The tributylstannyl precursor ATE-PEG4-CHC was synthesized by conjugation of ATE to amino pegylated colchicine NH2-PEG4-CHC. [131I]SIB-PEG4-CHC was radiosynthesized by electrophilic destannylation of the precursor with a yield of ~44%. The radiochemical purity (RCP) appeared to be >95% by a Sep-Pak cartridge purification. [131I]SIB-PEG4-CHC was lipophilic and was stable at room temperature. Biodistribution studies in tumor-bearing mice showed that [131I]SIB-PEG4-CHC cleared from background rapidly, and didn’t deiodinate in vivo. However, the poor tumor localization excluded it from further investigations as a tumor-targeted radiopharmaceuticals.

  • Collapse
  • Expand
  • Top

To see the editorial board, please visit the website of Springer Nature.

Manuscript Submission: HERE

For subscription options, please visit the website of Springer Nature.

Journal of Radionalytical and Nuclear Chemistry
Language English
Size A4
Year of
Foundation
1968
Volumes
per Year
1
Issues
per Year
12
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Springer Nature Switzerland AG
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0236-5731 (Print)
ISSN 1588-2780 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2022 0 0 0
May 2022 1 0 0
Jun 2022 0 0 0
Jul 2022 0 0 0
Aug 2022 0 0 0
Sep 2022 0 0 0
Oct 2022 0 0 0